Log in

NYSE:AMRXAmneal Pharmaceuticals Stock Price, Forecast & News

$4.97
+0.28 (+5.97 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.79
Now: $4.97
$5.00
50-Day Range
$2.87
MA: $3.67
$4.69
52-Week Range
$2.27
Now: $4.97
$8.53
Volume2.63 million shs
Average Volume1.91 million shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.17 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.19 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$1.49 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMRX shares have increased by 52.9% and is now trading at $4.97. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amneal Pharmaceuticals.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Amneal Pharmaceuticals.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) issued its quarterly earnings results on Monday, May, 11th. The company reported $0.20 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.09 by $0.11. The business earned $498.50 million during the quarter, compared to analysts' expectations of $446.12 million. Amneal Pharmaceuticals had a positive return on equity of 22.05% and a negative net margin of 11.85%. The business's revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 earnings per share. View Amneal Pharmaceuticals' earnings history.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Monday, May, 11th. The company provided earnings per share guidance of $0.45-0.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.50. The company issued revenue guidance of $1.88-1.98 billion, compared to the consensus revenue estimate of $1.87 billion.

What price target have analysts set for AMRX?

12 Wall Street analysts have issued 1 year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $2.50 to $14.00. On average, they expect Amneal Pharmaceuticals' share price to reach $5.91 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price. View analysts' price targets for Amneal Pharmaceuticals.

Has Amneal Pharmaceuticals been receiving favorable news coverage?

Headlines about AMRX stock have trended negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news aboutAmneal Pharmaceuticals.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Exelixis (EXEL), Intelsat (I), Micron Technology (MU), Nektar Therapeutics (NKTR), Teva Pharmaceutical Industries (TEVA), AbbVie (ABBV), Amarin (AMRN) and Alibaba Group (BABA).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (5.12%), BlackRock Inc. (3.11%), State Street Corp (0.81%), Geode Capital Management LLC (0.57%), Federated Hermes Inc. (0.49%) and Bank of New York Mellon Corp (0.42%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View institutional ownership trends for Amneal Pharmaceuticals.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Squarepoint Ops LLC, Morgan Stanley, Nuveen Asset Management LLC, Wellington Management Group LLP, Alambic Investment Management L.P., Deutsche Bank AG, and BlackRock Inc.. View insider buying and selling activity for Amneal Pharmaceuticals.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Russell Investments Group Ltd., Geode Capital Management LLC, Globeflex Capital L P, Invesco Ltd., Connor Clark & Lunn Investment Management Ltd., Mackenzie Financial Corp, and State Street Corp. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark. View insider buying and selling activity for Amneal Pharmaceuticals.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.97.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.49 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.